Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 38

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 38
---
 price of US$ per share would increase or decrease, as applicable, our pro forma net tangible book value per share to new investors by US$ , and would increase or decrease, as applicable, dilution in net tangible book value per share to new investors in this offering by US$ , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1,000,000 shares in the number of shares offered by us would increase or decrease, as applicable, our pro forma net tangible book value by US$ per share and increase or decrease, as applicable, the dilution in net tangible book value per share to new investors by US$ per share, assuming the assumed offering price remains the same, and after deducting commissions and estimated offering expenses payable by us. The pro forma information discussed above is illustrative only and will be adjusted based on the actual offering price and other terms of this offering to be determined at pricing. The above illustration of dilution in net tangible book value per share to new investors participating in this offering assumes no exercise of outstanding convertible bond or warrants as of December 31 ,2024 to purchase our common shares. The exercise of outstanding convertible bond and warrants having an exercise price less than the initial public offering price or the conversion of convertible debentures for no additional consideration will increase dilution to new investors. In addition, we may choose to raise additional capital depending on market conditions, our capital requirements and strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders. The following information is presented as of December 31, 2024:

|                                                                            |     | Existing shareholder 
 31/12/2024           |          |   |
|:---------------------------------------------------------------------------|:----|:---------------------|---------:|:--|
| Total comprehensive income attributable to the shareholders of the company |     | $                    | (498,480 | ) |
| Earning per share – basic                                                  |     |                      |    (66.2 | ) |
| - diluted                                                                  |     |                      |   (31.90 | ) |
| Weighted average shares outstanding – Basic                                |     |                      |    7,162 |   |
| -